Helus Pharma Inc. (HELP)
Helus Pharma Inc. (HELP) is a Healthcare stock tracked by StreetAlpha. It last closed at $6.11 on Nov 20, down 9.88% on the day. Over the last 12 months HELP insiders bought $9.7M of stock on the open market and sold $0, according to SEC Form 4 filings.
Key Stats
Fiscal 2025Not reported for this period.
From HELP's SEC filings, latest 40-F for the period ending Mar 31, 2025 (filed Jun 29). Figures are in CAD. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on HELP
Technical AnalysisPrices may be delayed
The stock is 45% below its 20 day and 74% below its 50 day average. It is 28% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 24), oversold. The nearest support is the Pivot S1 at $5.86, and the nearest resistance the Pivot at $6.30.
| RSI (14) | 24.26 | Oversold below 30 | Oversold |
| MACD | -1.06 | Below its signal line | Bearish |
| Stochastic | 4.1 | Near the bottom of its range | Oversold |
| ADX (14) | 27.5 | Trending down | |
| Williams %R | -98.4 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -177.8 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −31.8% | Change over 10 sessions | Bearish |
| ATR (14) | $0.91 | Typical daily range, 14.9% of price |
| RSI (14) | 34.68 | Weak, oversold below 30 | Neutral |
| MACD | 0.41 | Below its signal line | Bearish |
| Stochastic | 9.8 | Near the bottom of its range | Oversold |
| ADX (14) | 34.8 | Trending down | |
| Williams %R | -99.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -115.5 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −52.9% | Change over 10 sessions | Bearish |
| ATR (14) | $1.85 | Typical daily range, 30.3% of price |
What happened before
See how HELP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options FlowPrices may be delayed
90DNo whale options trades in HELP in the last 90 days.
HELP Institutional Ownership
Full report →- ▲9 buying vs 0 selling
- ●Shares held by funds +0.0%
- ●Funds holding +9
- ●No superinvestor moves
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 9 | – | – |
| In funds' top 10 | 0 | – | – |
| Held by funds | – | – | – |
| New / increased | 9 / 0 | – | – |
| Reduced / sold out | 0 / 0 | – | – |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
HELP Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 29 | Greg CaversCFO | Buy | 3,000 | $12.91 | $39K |
| Sep 21 | Michael HalsteadCEO | Buy | 100,000 | $13.47 | $1.3M |
| Sep 8 | Eric H. L. SoExecutive Chair | Buy | 100,000 | $12.39 | $1.2M |
| Sep 8 | Paul GlavineChief Growth Officer | Buy | 100,000 | $12.47 | $1.2M |
| Sep 8 | Paul GlavineChief Growth Officer | Buy | 100,000 | $12.47 | $1.2M |
| Sep 4 | Eric H. L. SoExecutive Chair | Buy | 100,000 | $12.09 | $1.2M |
From SEC Form 4 filings by HELP's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HELP is in one of them and how their past HELP trades turned out.
HELP News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered HELP in an article yet. Here's the latest on the wider market.
- Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder
- Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights
- Helus Pharma to Present Topline Results from Phase 3 APPROACH
- Condensed Interim Consolidated Financial Statements
- Item 1. Name and Address of Company
- Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
- Helus Pharma Announces Co-Founders' Transition from Executive
- Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026